Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs HSBC Holdings plc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $109.67 (market cap $12.58B), while HSBC Holdings plc trades at $93.24 (market cap $319.39B). The key difference: HSBC Holdings plc is far larger — about 25.4× Halozyme Therapeutics Inc. Common Stock's market cap, and HSBC Holdings plc pays a 4% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and HSBC Holdings plc for 36 Days on average.
| HALO | HSBC | |
|---|---|---|
Market Cap | $12.58B | $319.39B |
Volume | 2,179,278 | 2,543,839 |
Sector | Health | Financials |
52-Week High | $115.22 | $107.86 |
52-Week Low | $61.63 | $65.67 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $14.49B | $216.95B |
Dividend Yield | — | 4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HSBC trades at $93.71, down 3.97% today, with bearish technical signals dominating. The stock shows solid fundamentals with a P/E of 13.39 and net income margin of 34.54%, while recent earnings show mixed results with two beats and one miss. Recent corporate developments include expansion in technology banking and wealth management services, alongside strategic exits from lower-growth markets like Germany.
The outlook remains cautiously optimistic given strong profitability metrics and strategic growth initiatives, though near-term technical weakness and CFO transition risks warrant monitoring. Analyst consensus leans neutral with 52.38% hold ratings, reflecting balanced views on HSBC's Asia-focused growth strategy versus execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
